I'll Play, Says Jim Cramer About Bristol-Myers (BMY) [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 price target for Bristol-Myers Squibb Company (NYSE:BMY) on December 4th. Jefferies' coverage came on the same day that Scotiabank bumped the share price target to $53 from $45 and kept a Sector Perform rating. The bank cited Bristol-Myers Squibb Company (NYSE:BMY)'s pipeline as driving its enthusiasm. Additionally, on December 12th, Guggenheim had set a $62 price target and a Buy rating, as per The Fly. Photo by Myriam Zilles on Unsplash This flurry of analyst coverage comes as Bristol-Myers Squibb Company (NYSE:BMY) moves forward with regulatory oversight. As an example, on December 4th the firm announced that the Food and Drug Administration had granted traditional approval to its Breyanzi drug for certain patients with relapsed or refractory (R/R) marginal zone
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Takeda says $4B TYK2 drug succeeds in large psoriasis studies [Yahoo! Finance]Yahoo! Finance
- Syremis Therapeutics Launches with $165M to Develop Best-in-Class Medicines for Mental Health Conditions [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026Business Wire
- Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Canada Welcomes Positive CDA Recommendation for OPDIVO® Plus YERVOY® as First-Line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
BMY
Earnings
- 10/31/25 - Beat
BMY
Sec Filings
- 11/18/25 - Form 8-K
- 11/12/25 - Form CERT
- 11/10/25 - Form 8-A12B
- BMY's page on the SEC website